Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics, hospital antifungals and cancer treatments. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in clinical development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.Year founded
Grenzacherstrasse 487, 4058 Basel – Switzerland
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.